Cotargeting DNA topoisomerase II enhances efficacy of RAS-targeted therapy in KRAS-mutant cancer models

Journal:

Journal of Clinical Investigation

Published:

2026-02-16

DOI:

10.1172/jci197192

Affiliations:

7

Authors:

13

Go to article

Institutions	Authors	Share
Emory University, United States of America (USA)	4.000000	0.31
Predicine, Inc., United States of America (USA)	3.000000	0.23
Tongji Hospital (TJH), HUST, China	2.000000	0.15
The Winship Cancer Institute of Emory University, United States of America (USA)	2.000000	0.15
Second Xiangya Hospital, CSU, China	1.000000	0.08
Shanghai Municipal Hospital of Traditional Chinese Medicine, China	0.500000	0.04
West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), SCU, China	0.500000	0.04

Interested in Oncology and Carcinogenesis?